≡

Multiplex Assay Kit for Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay)

GPATC7; GPATCH7; VG5Q; Angiogenic factor VG5Q; G patch domain-containing protein 7; Vasculogenesis gene on 5q protein

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 99-105 102
EDTA plasma(n=5) 81-94 84
heparin plasma(n=5) 79-97 89
sodium citrate plasma(n=5) 96-105 101

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 92-101% 89-103% 92-101% 86-103%
EDTA plasma(n=5) 79-92% 87-96% 96-105% 99-105%
heparin plasma(n=5) 86-96% 90-98% 98-105% 78-104%
sodium citrate plasma(n=5) 80-101% 84-101% 98-105% 98-105%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:AGGF1) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease Role of microRNA-27a in down-regulation of angiogenic factor AGGF1 under hypoxia associated with high-grade bladder urothelial carcinoma Pubmed:24462738
Cancer Management and Research IL-17 induces macrophages to M2-like phenotype via NF-κB Pubmed: 30323677
Cellular Physiology and Biochemistry Sinoporphyrin Sodium-Mediated Sonodynamic Therapy Inhibits RIP3 Expression and Induces Apoptosis in the H446 Small Cell Lung Cancer Cell Line Pubmed: 30562734
Catalog No. Related products for research use of Mus musculus (Mouse) Organism species Applications (RESEARCH USE ONLY!)
RPL178Mu01 Recombinant Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) Positive Control; Immunogen; SDS-PAGE; WB.
RPL178Mu02 Recombinant Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) Positive Control; Immunogen; SDS-PAGE; WB.
PAL178Mu02 Polyclonal Antibody to Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) WB; IHC; ICC; IP.
PAL178Mu01 Polyclonal Antibody to Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) WB; IHC; ICC; IP.
SEL178Mu ELISA Kit for Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) Enzyme-linked immunosorbent assay for Antigen Detection.
LML178Mu Multiplex Assay Kit for Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.